Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Archean Chemical Industries is an India-based specialty chemicals manufacturer focused on bromine and industrial salt production, operating integrated facilities in Gujarat with captive seawater resources. The company serves pharmaceutical, agrochemical, and oil & gas drilling sectors with bromine derivatives and specialty chemicals. Stock performance is driven by bromine pricing dynamics, capacity utilization at its 75,000 MTPA bromine facility, and demand from downstream industrial applications.
Archean operates an integrated seawater-based extraction model with captive brine resources in Gujarat, providing significant cost advantages versus synthetic bromine producers. The company extracts bromine, salt, and other minerals from seawater through solar evaporation and chemical processing, selling both commodity-grade and value-added specialty derivatives. Pricing power derives from being one of few integrated bromine producers globally (China dominates 60% of supply), with margins expanding when bromine prices rise above $4,000-5,000 per ton. The business benefits from vertical integration - seawater intake to finished specialty chemicals - reducing raw material volatility and enabling higher-margin derivative production.
Global bromine spot prices and contract pricing trends - benchmark prices in China and US Gulf Coast markets directly impact realization
Capacity utilization rates at Gujarat facilities and progress on expansion projects - new capacity commissioning drives volume growth
Demand from pharmaceutical and agrochemical sectors - bromine derivatives used in API synthesis and crop protection chemicals
Chinese supply dynamics - production curtailments, environmental regulations, or export restrictions create pricing volatility
Oil & gas drilling activity - bromine-based completion fluids demand correlates with upstream capex cycles
Chinese supply dominance and potential capacity additions - China controls 60% of global bromine supply; large-scale expansions or export policy changes could flood markets and pressure pricing
Environmental regulations on seawater extraction and brine discharge - increasingly stringent coastal zone regulations in India could limit expansion or increase compliance costs
Substitution risk in flame retardants - regulatory shifts toward non-halogenated alternatives in electronics and construction materials could erode long-term bromine demand
Competition from Dead Sea bromine producers (Israel Chemicals, Jordan Bromine) with lower extraction costs from hypersaline brines
Synthetic bromine production technology improvements reducing cost advantages of natural extraction
Customer backward integration - large pharmaceutical or agrochemical companies developing captive bromine derivative production
Negative free cash flow during expansion phase - $2.6B capex against $1.8B operating cash flow creates funding gap, though strong balance sheet (0.15x D/E) provides cushion
Execution risk on capacity expansions - delays or cost overruns on new evaporation ponds and processing units could pressure returns, especially if bromine prices soften during ramp-up
Working capital intensity in chemical inventory - bromine and derivatives require storage; price declines create inventory writedown risk
moderate-to-high - Bromine demand is tied to industrial production cycles through pharmaceutical manufacturing, agrochemical production, and oil field services. During economic expansions, pharmaceutical API production increases, crop protection chemical demand rises with agricultural activity, and upstream oil & gas drilling intensifies. However, some end-markets (pharma) provide counter-cyclical stability. The -21.7% revenue decline and -49% earnings drop suggest recent cyclical headwinds, likely from bromine price corrections after 2023-2024 peaks and softer industrial demand.
Moderate sensitivity through two channels: (1) The company is in heavy capex mode ($2.6B spend creating negative FCF), so rising rates increase project financing costs and hurdle rates for expansion ROI, though low 0.15x debt/equity suggests limited current leverage. (2) Higher rates can dampen industrial capex and pharmaceutical R&D spending, reducing bromine derivative demand. The 23.3x EV/EBITDA valuation makes the stock sensitive to discount rate changes - rising rates compress growth multiples for capital-intensive chemical producers.
Minimal direct credit exposure as the business is B2B chemicals sales with typical 30-90 day payment terms to industrial customers. However, customer credit quality matters - pharmaceutical and agrochemical companies are generally investment-grade, but smaller specialty chemical buyers and oil service companies carry higher default risk during downturns. The 3.0x current ratio and low leverage provide strong liquidity buffer.
growth - The stock attracts growth investors betting on India's specialty chemicals expansion story, capacity ramp-up driving volume growth, and potential margin expansion as new assets reach full utilization. The 6.2x P/S and 23.3x EV/EBITDA multiples reflect growth expectations despite recent earnings decline. However, negative FCF and cyclical earnings volatility deter income-focused investors. The 32.8% one-year return (despite recent pullback) suggests momentum traders also participate during bromine price rallies.
high - Chemical commodity price exposure, binary capacity expansion outcomes, and emerging market listing (India) create elevated volatility. The -15.6% six-month decline followed by 32.8% one-year gain illustrates boom-bust cyclicality. Beta likely exceeds 1.2x relative to Indian equity indices, with additional volatility from bromine price swings (which can move 30-50% annually) and project execution updates.
